(Bloomberg) -- Patients with asthma or a progressive lung disease are less likely to abandon treatment with Novartis AG’s AirFluSal Forspiro inhaler than with GlaxoSmithKline Plc’s Seretide Diskus, the Swiss drugmaker said, citing a one-year study.

With the Novartis device, patients showed a persistence rate of 23 percent, compared with 11 percent for the Glaxo one, according to the study, which relied on a German pharmacy database and whose results were published in the Journal of Allergy and Clinical Immunology: In Practice.

To contact the reporter on this story: Marthe Fourcade in Paris at To contact the editor responsible for this story: Chitra Somayaji at

©2016 Bloomberg L.P.